Skip to main content

Eye stem cell transplant to treat blindness bolsters retinal function in monkeys

Image
By

Retinal cell transplants are considered to be an attractive approach for treating blindness. Question is, where do you source the cells? 

An international research team of scientists from Singapore’s Agency for Science, Technology and Research (A*STAR), the Icahn School of Medicine at Mount Sinai in New York and Germany’s Eye Clinic Sulzbach is using a type of stem cell in the eye to grow the pigmented layer of retina that’s essential for vision. The approach is showing promise in monkeys.

The findings suggest that these retinal pigment epithelium (RPE) stem cell-derived RPE, or hRPESC-RPE, may be a useful source for cell replacement therapies to treat RPE-related blindness caused by diseases such as macular degeneration, the researchers suggest. The results are published in the journal Stem Cell Reports.

RPE is a layer of tissue that supports the neurosensory retina and is critical for vision. An estimated 200 million people live with diseases associated with RPE dysfunction, including macular degeneration. Early attempts at RPE replacement used cells from the patient—an approach with limitations—scientists have been searching for treatment using different populations of stem cells.

In 2012, scientists identified a type of adult cell in the RPE that's normally dormant but that can be activated to take on a stem-cell-like state with self-renewing ability. These cells have the potential to differentiate into RPE cells and could therefore be used for RPE replacement therapies, the A*STAR-led team figured.

In their study, the researchers took hRPESC-RPE from donated adult eyes and grew them into RPE monolayers. When transplanted into the eyes of monkeys on a polymer scaffold, the RPE patches stably integrated for at least three months.

The stem cell-derived RPE patches partially took over and were able to support normal light-sensing function, the team showed. What’s more, the method didn’t cause vision-blocking retinal scarring that has been seen with other experimental approaches.

Multiple types of stem cells, including human embryonic stem cells and human-induced pluripotent stem cells, have been proposed as alternative sources for retinal replacement. A team led by Mount Sinai previously used gene transfer to activate a type of retinal cells called Müller glial to adopt stem-cell-like characteristics. The team prompted the cells to divide into light-sensing rod photoreceptor cells in blind mice.

Researchers led by the National Institutes of Health’s National Eye Institute used five chemicals to turn skin cells directly into rod photoreceptors.

The A*STAR-led researchers believe their study demonstrates the potential of using hRPESC-RPE transplants as a treatment for macular degeneration. Further studies are needed to test the method in monkey models of eye disease to gauge the therapeutic effect, the researcher suggested.

If the cells succeed, they could serve as an unlimited resource for human RPE. Because the cells are harvested from human eyes, the researchers suggested establishing hRPESC-RPE donor banks to provide cells that match individual patients so there is no immune rejection.


Source : https://www.fiercebiotech.com/research/eye-stem-cell-transplant-as-potential-blindness-treatment-shows-promise-monkey

Comments

Post a Comment

Popular posts from this blog

The Dawn Of A New Era Of Regenerative Medicine: Tissue Engineering Comes Of Age

By
The Dawn Of A New Era Of Regenerative Medicine: Tissue Engineering Comes Of Age   The field of regenerative medicine reached a remarkable milestone recently when four women regained full sexual function after the successful implantation of lab-grown vaginas created from their own cells. The women, aged thirteen to eighteen, were born with a rare medical condition called Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) which left them with an abnormal or missing vagina. Each woman underwent a newly engineered procedure that involved taking samples of the patient's own cells and growing them into tissue. This tissue was then placed on a scaffold that was hand-sewn with collagen-like fibers and uniquely shaped to fit each woman’s vaginal cavity. Once the organ fully matured, it was implanted into a canal in each woman’s pelvis, along with the hand-sewn scaffolding. Within six months, the biodegradable scaffolding dissolved and, in each of the four women, the lab-grown vaginas began fun...
Post a Comment
Read more

Black fungus detected in Covid-19 survivors, 8 lose eyesight in Surat | MUCORMYCOSIS

By
 Black fungus detected in Covid-19 survivors, 8 lose eyesight in Surat | MUCORMYCOSIS At least 40 cases of mucormycosis, also known as black fungus, have been reported from Surat in Gujarat among those who have recovered from Covid-19. Of the 40, eight have lost their eyesight. What is this infection and who is more vulnerable? Cases of mucormycosis, commonly known as black fungus, have been reported from Gujarat among those who have recovered from Covid-19. The number of such cases has increased as Gujarat sees an exponential rise in coronavirus infections. At least eight persons were reported to have lost their eyesight in Surat due to mucormycosis (MM) after recovering from Covid-19. They had to be admitted to hospitals for the sudden loss of vision. In the past 15 days, Surat has reported at least 40 cases of mucormycosis or black fungus including eight who have lost their eyesight. The infection, triggered by Covid-19, is treatable but if left untreated or if the treatment is ...
Post a Comment
Read more

US Moves to Shut Down 2 Big Stem Cell Therapy Clinics

By
Federal authorities Wednesday moved to shut down two of the country’s most prominent for-profit providers of stem cell therapy, one of them a network of clinics with more than 100 offices in the United States, including several in the Bay Area. The Food and Drug Administration filed two complaints in federal court requesting permanent injunctions that would stop Florida-based U.S. Stem Cell Clinic and the California Stem Cell Treatment Center from marketing therapies. Both companies have previously been called out by the FDA for providing unproven, unapproved therapies that could put patients at risk. The injunction requests are an aggressive move by the FDA to patrol the consumer stem cell market. The agency has come under mounting pressure by scientists and patient advocates to increase oversight of the growing consumer market, which has been allowed to flourish for years. “In the two cases filed today, the clinics and their leadership have continued to disregard th...
Post a Comment
Read more